drugset / Trial / NCT03764085

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.

NCT03764085

Phase 4 Completed 180 enrolled Yuria-Pharm
RandomizedParallel-groupSingle-blindTreatment

Summary

This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of sepsis. Half of participants will receive Rheosorbilact® in complex therapy, while the other half will receive Ringer's Lactate in complex therapy.

Timeline

Start
2016-12-06
Primary completion
2019-12-11
Completion
2019-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rheosorbilact® Unknown 600 ml Intravenous
Subject Rheosorbilact® Unknown 1000 ml Intravenous
Comparator Ringer's Lactate Other / unclassified 1000 ml Intravenous
Comparator Ringer's Lactate Other / unclassified 2500 ml Intravenous